Current progress in neoantigen-based dendritic cell vaccines for solid tumors
Immunotherapy, particularly immune checkpoint inhibitors (ICIs) programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), has heralded a new era of tumor treatment. Although ICIs have clinical benefits, their complex heterogeneity and diverse...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
China Anti-Cancer Association
2025-10-01
|
| coleção: | Cancer Biology & Medicine |
| Assuntos: | |
| Acesso em linha: | https://www.cancerbiomed.org/content/22/10/1143 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|